VFEND Drug Patent Profile
✉ Email this page to a colleague
When do Vfend patents expire, and when can generic versions of Vfend launch?
Vfend is a drug marketed by Pf Prism Cv and is included in three NDAs.
The generic ingredient in VFEND is voriconazole. There are fourteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the voriconazole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vfend
A generic version of VFEND was approved as voriconazole by MYLAN PHARMS INC on April 22nd, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VFEND?
- What are the global sales for VFEND?
- What is Average Wholesale Price for VFEND?
Summary for VFEND
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 127 |
Patent Applications: | 5,541 |
Drug Prices: | Drug price information for VFEND |
What excipients (inactive ingredients) are in VFEND? | VFEND excipients list |
DailyMed Link: | VFEND at DailyMed |
Pharmacology for VFEND
Drug Class | Azole Antifungal |
Mechanism of Action | Cytochrome P450 2C19 Inhibitors Cytochrome P450 2C9 Inhibitors Cytochrome P450 3A4 Inhibitors |
Paragraph IV (Patent) Challenges for VFEND
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
VFEND | Oral Suspension | voriconazole | 40 mg/mL | 021630 | 1 | 2010-10-08 |
VFEND | For Injection | voriconazole | 200 mg/vial | 021267 | 1 | 2008-09-12 |
VFEND | Tablets | voriconazole | 50 mg and 200 mg | 021266 | 1 | 2008-04-14 |
US Patents and Regulatory Information for VFEND
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pf Prism Cv | VFEND | voriconazole | FOR SUSPENSION;ORAL | 021630-001 | Dec 19, 2003 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Pf Prism Cv | VFEND | voriconazole | TABLET;ORAL | 021266-002 | May 24, 2002 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Pf Prism Cv | VFEND | voriconazole | INJECTABLE;INTRAVENOUS | 021267-001 | May 24, 2002 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Pf Prism Cv | VFEND | voriconazole | TABLET;ORAL | 021266-001 | May 24, 2002 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VFEND
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pf Prism Cv | VFEND | voriconazole | FOR SUSPENSION;ORAL | 021630-001 | Dec 19, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Pf Prism Cv | VFEND | voriconazole | TABLET;ORAL | 021266-001 | May 24, 2002 | ⤷ Sign Up | ⤷ Sign Up |
Pf Prism Cv | VFEND | voriconazole | FOR SUSPENSION;ORAL | 021630-001 | Dec 19, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Pf Prism Cv | VFEND | voriconazole | TABLET;ORAL | 021266-002 | May 24, 2002 | ⤷ Sign Up | ⤷ Sign Up |
Pf Prism Cv | VFEND | voriconazole | TABLET;ORAL | 021266-001 | May 24, 2002 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for VFEND
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Pfizer Europe MA EEIG | Vfend | voriconazole | EMEA/H/C/000387 Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Vfend should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. |
Authorised | no | no | no | 2002-03-19 | |
Accord Healthcare S.L.U. | Voriconazole Accord | voriconazole | EMEA/H/C/002669 Voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged two years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Voriconazole Accord should be administered primarily to patients with progressive, possibly life-threatening infections. |
Authorised | yes | no | no | 2013-05-16 | |
Hikma Farmaceutica (Portugal) S.A. | Voriconazole Hikma (previously Voriconazole Hospira) | voriconazole | EMEA/H/C/003737 Voriconazole is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT)recipients. |
Authorised | yes | no | no | 2015-05-27 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for VFEND
See the table below for patents covering VFEND around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Luxembourg | 90960 | ⤷ Sign Up | |
New Zealand | 247205 | INTERMEDIATE COMPOUNDS: 4-ETHYL-5-FLUOROPYRIMIDINE AND 4-CHLORO-6-ETHYL-5-FLUOROPYRIMIDINE | ⤷ Sign Up |
Hungary | T56361 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 9402518 | ⤷ Sign Up | |
Yugoslavia | 48105 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VFEND
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0440372 | 90960 | Luxembourg | ⤷ Sign Up | |
0440372 | 02C0030 | France | ⤷ Sign Up | PRODUCT NAME: VORICONAZOLE; NAT. REGISTRATION NO/DATE: EU/1/02/212/001-025 20020319; FIRST REGISTRATION: EU/1/02/212/001-25 20020319 |
0440372 | SPC/GB02/031 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: VORICONAZOLE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/02/212/001-025 20020319 |
1001813 | PA2003005 | Lithuania | ⤷ Sign Up | PRODUCT NAME: VORICONAZOLIS; REGISTRATION NO/DATE: 02/7890/8 20021002 |
0440372 | C300100 | Netherlands | ⤷ Sign Up | PRODUCT NAME: VORICONAZOLUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/02/212/001-025 20020319 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |